St. Paul’s Hospital Cardiac Amyloidosis Clinic is involved in many types of amyloidosis research. Patients attending the clinic may be invited to participate in a study.
Some of our current and recently completed studies are listed below. Please ask your medical team if any clinical trial opportunities are available for you:
A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (CLEOPATTRA)
A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
A Non-Interventional, Prospective, Multi-country Study Collecting Real-World Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis (MaesTTRo)
Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (ATTR CM)
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM)
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
A Phase 3 Global, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin Mediated Amyloid Cardiomyopathy (ATTR CM) (Cardio-TTRansform)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
A Phase 3 Multicenter, Open-Label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826-83) 20 mg or 80 mg (or Tafamidis (PF-06291826-00) 61 mg) in Subjects Diagnosed with Transthyretin Cardiomyopathy (ATTR-CM)
The Canadian Registry for Amyloidosis Research (CRAR)
For more information about our research program, please speak to a member of our clinic team or contact our research manager, Andrew Starovoytov, at [email protected].
Email: [email protected]
Phone: 604-875-5759
Fax: 604-694-6432
St. Paul’s Hospital Address:
5 C/D-5th Floor, Providence Building
1081 Burrard Street
Vancouver BC
V6Z 1Y6
